Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Last updated: March 24, 2025
Sponsor: AstraZeneca
Overall Status: Active - Recruiting

Phase

3

Condition

N/A

Treatment

Matched Capivasertib Placebo

Fulvestrant

Abemaciclib

Clinical Study ID

NCT04862663
D361DC00001
2020-004637-20
  • Ages 18-99
  • All Genders

Study Summary

A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

Eligibility Criteria

Inclusion

Key inclusion criteria for both phases:

  1. Adult females (pre-/peri-/ and post-menopausal), and adult males.

  2. Histologically confirmed HR+/ HER2- breast cancer determined from the most recent tumour sample (primary or metastatic) per the American Society of Clinical Oncology and College of American Pathologists guideline. To fulfil the requirement of HR+ disease, a breast cancer must express ER with or without co-expression of progesterone receptor.

  3. Eligible for fulvestrant therapy and at least one of the following: palbociclib, ribociclib, or abemaciclib, as per local investigator assessment. Previous tolerance to specific CDK4/6 inhibitors and dose levels required.

  4. Adequate organ and bone marrow functions.

  5. Consent to provide a mandatory FFPE tumour sample.

Key inclusion criteria only for phase III:

  1. Previous treatment with an ET (tamoxifen, AI, or oral SERD) as a single agent or in combination, with radiological evidence of breast cancer recurrence or progression while on, or within 12 months of, completing a (neo)adjuvant ET regimen.

  2. Provision of mandatory blood samples at screening for central testing using an investigational ctDNA test to be stratified based on PIK3CA/AKT1/PTEN status.

  3. Be eligible for fulvestrant and at least one out of palbociclib or ribociclib (depending on the available CDK4/6i options at time of enrolment), as per local investigator assessment.

  4. Have measurable lesion(s) according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1) or, in the absence of measurable disease, lytic or mixed bone lesions that can be assessed by computed tomography (CT) or magnetic resonance imaging (MRI).

Key exclusion criteria for both phases:

  1. History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence.

  2. Radiotherapy within 2 weeks prior to study treatment initiation.

  3. Major surgery or significant traumatic injury within 4 weeks of the first dose of study treatment.

  4. Persistent toxicities (CTCAE Grade >1) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss or peripheral sensory neuropathy) after consultation with the AstraZeneca study physician.

  5. Spinal cord compression, brain metastases or leptomeningeal metastases unless these lesions are definitively treated (eg. radiotherapy, surgery) and clinically stable off steroids for management of symptoms for at least 4 weeks prior to study treatment initiation.

  6. Any of the following cardiac criteria at screening:

(a). Mean resting corrected QT interval (QTcF): (i) Participants to be treated with palbociclib:: QTcF ≥ 470 ms obtained from the average of 3 consecutive (triplicate) ECGs (ii) Participants to be treated with ribociclib: QTcF ≥ 450 ms obtained from the average of 3 consecutive (triplicate) ECGs (iii) Participants to be treated with abemaciclib (Phase Ib only): QTcF ≥ 470 ms obtained from the average of 3 consecutive (triplicate) ECGs (b). Any clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third-degree heart block) (c). Any factors that increase the risk of QTc prolongation or risk of arrhythmic events (d). Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure New York Heart Association (NYHA) grade ≥ 2 (e). Uncontrolled hypotension (f) uncontrolled hypertension (g). Cardiac ejection fraction outside institutional range of normal or < 50% (whichever is higher)

  1. uncontrolled or high grade or symptomatic arrhythmia and atrial fibrillation

  2. Any of these clinically significant abnormalities of glucose metabolism at screening:

  3. . diabetes mellitus type I or type II requiring insulin treatment

  4. . Glycated haemoglobin (HbA1c) ≥ 8.0% (63.9 mmol/mol)

  5. Previous allogeneic bone marrow transplant or solid organ transplant.

Key exclusion criteria for the phase III only:

  1. Any prior treatment with, AKT, PI3K or mTOR inhibitors.

  2. Prior treatment with CDK4/6 inhibitors in the metastatic setting (prior CDK4/6 inhibitors permitted in the adjuvant setting provided there was a CDK4/6i treatment free interval of at least 12 months).

  3. More than 1 line of chemotherapy for metastatic disease.

  4. Any line of endocrine-based therapy for inoperable locally advanced or metastatic disease.

Study Design

Total Participants: 895
Treatment Group(s): 6
Primary Treatment: Matched Capivasertib Placebo
Phase: 3
Study Start date:
May 10, 2021
Estimated Completion Date:
August 14, 2029

Study Description

This Phase Ib/III study (CAPItello-292) aims to evaluate the efficacy, safety and the degree of added benefit of capivasertib combined with CDK4/6i and fulvestrant in participants with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer. Although the dosing regimens of capivasertib + fulvestrant and of CDK4/6i + fulvestrant are established separately, the dose and schedule for the triplet combinations (capivasertib + CDK4/6i + fulvestrant) need to be confirmed. Therefore, the initial dose finding Phase Ib part of the study will determine the recommended Phase III doses (RP3D) of the triplet combinations. The Phase III part of the study will evaluate the efficacy, safety and the degree of added benefit of the triplet combinations of capivasertib and fulvestrant with investigator's choice of CDK4/6i (either palbociclib or ribociclib at safe and tolerable doses, once identified) in comparison with a control arm (fulvestrant

  • investigator's choice of CDK4/6i [palbociclib or ribociclib]) in a ER+ HER2- maC high risk population that did not receive prior endocrine therapy in the advanced setting.

Connect with a study center

  • Research Site

    Buenos Aires, C1125ABD
    Argentina

    Active - Recruiting

  • Research Site

    Caba, C1425
    Argentina

    Suspended

  • Research Site

    Chivilcoy, B6620LUD
    Argentina

    Active - Recruiting

  • Research Site

    Rosario, 2000
    Argentina

    Active - Recruiting

  • Research Site

    Santa Fe, S2002RE
    Argentina

    Site Not Available

  • Research Site

    Darlinghurst, 2010
    Australia

    Active - Recruiting

  • Research Site

    Miranda, 2228
    Australia

    Site Not Available

  • Research Site

    Nedlands, 6009
    Australia

    Site Not Available

  • Research Site

    Perth, 6009
    Australia

    Site Not Available

  • Research Site

    Wahroonga, 2076
    Australia

    Active - Recruiting

  • Research Site

    Waratah, 2298
    Australia

    Active - Recruiting

  • Research Site

    Brasschaat, 2930
    Belgium

    Active - Recruiting

  • Research Site

    Bruxelles, 1200
    Belgium

    Active - Recruiting

  • Research Site

    Edegem, 2650
    Belgium

    Active - Recruiting

  • Research Site

    Haine-Saint-Paul, 7100
    Belgium

    Active - Recruiting

  • Research Site

    Leuven, 3000
    Belgium

    Active - Recruiting

  • Research Site

    Alfenas, 37130-000
    Brazil

    Active - Recruiting

  • Research Site

    Blumenau, 89010-340
    Brazil

    Active - Recruiting

  • Research Site

    Natal, 59075-740
    Brazil

    Active - Recruiting

  • Research Site

    Porto Alegre, 90035-903
    Brazil

    Active - Recruiting

  • Research Site

    Porto Velho, 76834-899
    Brazil

    Active - Recruiting

  • Research Site

    São Paulo, 04014-002
    Brazil

    Active - Recruiting

  • Research Site

    Taubaté, 12030-200
    Brazil

    Active - Recruiting

  • Research Site

    Teresina, 64049-200
    Brazil

    Active - Recruiting

  • Research Site

    Vitoria, 29043-260
    Brazil

    Active - Recruiting

  • Research Site

    Abbotsford, British Columbia V2S0C2
    Canada

    Active - Recruiting

  • Research Site

    Kelowna, British Columbia V1Y 5L3
    Canada

    Active - Recruiting

  • Research Site

    Winnipeg, Manitoba R3E 0V9
    Canada

    Site Not Available

  • Research Site

    Moncton, New Brunswick E1C 6Z8
    Canada

    Site Not Available

  • Research Site

    Halifax, Nova Scotia B3H 1V7
    Canada

    Active - Recruiting

  • Research Site

    Brampton, Ontario L6R 3J7
    Canada

    Active - Recruiting

  • Research Site

    Ottawa, Ontario K1H 8L6
    Canada

    Active - Recruiting

  • Research Site

    Sault Ste. Marie, Ontario P6A 2C4
    Canada

    Site Not Available

  • Research Site

    Toronto, Ontario M5B 1W8
    Canada

    Site Not Available

  • Research Site

    Sherbrooke, Quebec J1H 5N4
    Canada

    Active - Recruiting

  • Research Site

    Chicoutimi, G7H 5H6
    Canada

    Active - Recruiting

  • Research Site

    Montreal, H3T 1E2
    Canada

    Active - Recruiting

  • Research Site

    Beijing, 100044
    China

    Active - Recruiting

  • Research Site

    Bengbu, 233060
    China

    Active - Recruiting

  • Research Site

    Changchun, 130000
    China

    Active - Recruiting

  • Research Site

    Changsha, 410013
    China

    Active - Recruiting

  • Research Site

    Chengdu, 610041
    China

    Active - Recruiting

  • Research Site

    Chongqing, 400042
    China

    Active - Recruiting

  • Research Site

    Fuzhou, 350011
    China

    Site Not Available

  • Research Site

    Guangzhou, 510062
    China

    Active - Recruiting

  • Research Site

    Hangzhou, 310016
    China

    Active - Recruiting

  • Research Site

    Hefei, 230031
    China

    Active - Recruiting

  • Research Site

    Jinan, 250001
    China

    Active - Recruiting

  • Research Site

    Nanchang, 330006
    China

    Active - Recruiting

  • Research Site

    Nanjing, 210029
    China

    Active - Recruiting

  • Research Site

    Nanning, 530021
    China

    Active - Recruiting

  • Research Site

    Shandong,
    China

    Active - Recruiting

  • Research Site

    Shanghai, 200032
    China

    Active - Recruiting

  • Research Site

    Shenyang, 110016
    China

    Active - Recruiting

  • Research Site

    Urumqi, 830000
    China

    Site Not Available

  • Research Site

    Wuhan, 430060
    China

    Active - Recruiting

  • Research Site

    Xi'an, 710061
    China

    Active - Recruiting

  • Research Site

    Xian, 710100
    China

    Active - Recruiting

  • Research Site

    Xiangyang City, 441000
    China

    Active - Recruiting

  • Research Site

    Xuzhou, 221009
    China

    Active - Recruiting

  • Research Site

    Zhengzhou, 450008
    China

    Active - Recruiting

  • Research Site

    Aalborg, 9000
    Denmark

    Active - Recruiting

  • Research Site

    Aarhus N, 8200
    Denmark

    Active - Recruiting

  • Research Site

    Hillerød, 3400
    Denmark

    Active - Recruiting

  • Research Site

    Odense C, 5000
    Denmark

    Active - Recruiting

  • Research Site

    Bobigny, 93000
    France

    Site Not Available

  • Research Site

    Clermont Ferrand, 63011
    France

    Site Not Available

  • Research Site

    Limoges, 87042
    France

    Site Not Available

  • Research Site

    Lyon, 69008
    France

    Site Not Available

  • Research Site

    Plerin, 22190
    France

    Site Not Available

  • Research Site

    Rouen, 76021
    France

    Site Not Available

  • Research Site

    St Herblain, 44805
    France

    Active - Recruiting

  • Research Site

    Villejuif, 94805
    France

    Active - Recruiting

  • Research Site

    Augsburg, 86150
    Germany

    Active - Recruiting

  • Research Site

    Berlin, 13125
    Germany

    Active - Recruiting

  • Research Site

    Bottrop, 46236
    Germany

    Site Not Available

  • Research Site

    Dresden, 01307
    Germany

    Active - Recruiting

  • Research Site

    Erlangen, 91054
    Germany

    Site Not Available

  • Research Site

    Frankfurt, 65929
    Germany

    Site Not Available

  • Research Site

    Frankfurt am Main, 65929
    Germany

    Active - Recruiting

  • Research Site

    Freiburg, 79106
    Germany

    Site Not Available

  • Research Site

    Georgsmarienhütte, 49124
    Germany

    Active - Recruiting

  • Research Site

    Hamburg, 20357
    Germany

    Active - Recruiting

  • Research Site

    Hannover, 30625
    Germany

    Active - Recruiting

  • Research Site

    Heilbronn, 74078
    Germany

    Site Not Available

  • Research Site

    Kiel, 24105
    Germany

    Active - Recruiting

  • Research Site

    Leipzig, 04103
    Germany

    Active - Recruiting

  • Research Site

    Mannheim, 68167
    Germany

    Site Not Available

  • Research Site

    Mönchengladbach, 41061
    Germany

    Active - Recruiting

  • Research Site

    Münster, 48149
    Germany

    Site Not Available

  • Research Site

    Regensburg, 93053
    Germany

    Active - Recruiting

  • Research Site

    Stade, 21680
    Germany

    Site Not Available

  • Research Site

    Trier, 54290
    Germany

    Site Not Available

  • Research Site

    Ulm, 89075
    Germany

    Active - Recruiting

  • Research Site

    Bangalore, 560004
    India

    Active - Recruiting

  • Research Site

    JAipur, 302022
    India

    Site Not Available

  • Research Site

    Jaipur, 302017
    India

    Site Not Available

  • Research Site

    Mohali, 160055
    India

    Active - Recruiting

  • Research Site

    Mysuru, 570017
    India

    Active - Recruiting

  • Research Site

    Nagpur, 440001
    India

    Active - Recruiting

  • Research Site

    New Delhi, 110076
    India

    Active - Recruiting

  • Research Site

    Pondicherry, 605006
    India

    Suspended

  • Research Site

    Vadodara, 391760
    India

    Active - Recruiting

  • Research Site

    Varanasi, 221005
    India

    Active - Recruiting

  • Research Site

    Aviano, 33081
    Italy

    Site Not Available

  • Research Site

    Bologna, 40138
    Italy

    Site Not Available

  • Research Site

    Catanzaro, 88100
    Italy

    Site Not Available

  • Research Site

    Firenze, 50141
    Italy

    Active - Recruiting

  • Research Site

    Milan, 20141
    Italy

    Site Not Available

  • Research Site

    Milano, 20132
    Italy

    Site Not Available

  • Research Site

    Misterbianco, 95045
    Italy

    Site Not Available

  • Research Site

    Napoli, 80131
    Italy

    Site Not Available

  • Research Site

    Padova, 35128
    Italy

    Site Not Available

  • Research Site

    Prato, 59100
    Italy

    Active - Recruiting

  • Research Site

    Reggio Emilia, 422122
    Italy

    Site Not Available

  • Research Site

    Roma, 00168
    Italy

    Site Not Available

  • Research Site

    Rozzano, 20089
    Italy

    Site Not Available

  • Research Site

    Chiba-shi, 260-8717
    Japan

    Site Not Available

  • Research Site

    Chuo-ku, 104-0045
    Japan

    Active - Recruiting

  • Research Site

    Hidaka-shi, 350-1298
    Japan

    Active - Recruiting

  • Research Site

    Hirakata-shi, 573-1191
    Japan

    Site Not Available

  • Research Site

    Hiroshima-shi, 730-8518
    Japan

    Active - Recruiting

  • Research Site

    Isehara-shi, 259-1193
    Japan

    Active - Recruiting

  • Research Site

    Kagoshima-shi, 892-0833
    Japan

    Active - Recruiting

  • Research Site

    Koto-ku, 135-8550
    Japan

    Active - Recruiting

  • Research Site

    Kyoto-shi, 606-8507
    Japan

    Active - Recruiting

  • Research Site

    Matsuyama-shi, 791-0280
    Japan

    Site Not Available

  • Research Site

    Nagoya-shi, 464-8681
    Japan

    Site Not Available

  • Research Site

    Naha-shi, 901-0154
    Japan

    Active - Recruiting

  • Research Site

    Okayama-shi, 700-8558
    Japan

    Site Not Available

  • Research Site

    Osaka-shi, 541-8567
    Japan

    Site Not Available

  • Research Site

    Ota-shi, 373-8550
    Japan

    Site Not Available

  • Research Site

    Sapporo-shi, 060-8638
    Japan

    Site Not Available

  • Research Site

    Sendai-shi, 980-8574
    Japan

    Site Not Available

  • Research Site

    Shimotsuke-shi, 329-0498
    Japan

    Site Not Available

  • Research Site

    Shinagawa-ku, 142-8666
    Japan

    Active - Recruiting

  • Research Site

    Shinjuku-ku, 162-8655
    Japan

    Site Not Available

  • Research Site

    Suita-shi, 565-0871
    Japan

    Active - Recruiting

  • Research Site

    Takasaki-shi, 370-0829
    Japan

    Active - Recruiting

  • Research Site

    Tsu-shi, 514-8507
    Japan

    Active - Recruiting

  • Research Site

    Yokohama-shi, 241-8515
    Japan

    Site Not Available

  • Research Site

    Goyang-si, 10408
    Korea, Republic of

    Active - Recruiting

  • Research Site

    Seoul, 06273
    Korea, Republic of

    Active - Recruiting

  • Research Site

    George Town, 10350
    Malaysia

    Active - Recruiting

  • Research Site

    Kuala Lumpur, 50586
    Malaysia

    Active - Recruiting

  • Research Site

    Kuching, 93586
    Malaysia

    Active - Recruiting

  • Research Site

    Pulau Pinang, 10450
    Malaysia

    Active - Recruiting

  • Research Site

    Selangor, 62250
    Malaysia

    Active - Recruiting

  • Research Site

    Bialystok, 15-027
    Poland

    Site Not Available

  • Research Site

    Bydgoszcz, 85-796
    Poland

    Site Not Available

  • Research Site

    Gdańsk, 80-952
    Poland

    Site Not Available

  • Research Site

    Koszalin, 75-581
    Poland

    Site Not Available

  • Research Site

    Kraków, 31-501
    Poland

    Site Not Available

  • Research Site

    Lodz, 91-211
    Poland

    Site Not Available

  • Research Site

    Lublin, 20-090
    Poland

    Site Not Available

  • Research Site

    Rzeszów, 35-326
    Poland

    Site Not Available

  • Research Site

    Warszawa, 02-781
    Poland

    Completed

  • Research Site

    Łódź, 90-302
    Poland

    Site Not Available

  • Research Site

    Barcelona, 8035
    Spain

    Active - Recruiting

  • Research Site

    Granada, 18014
    Spain

    Active - Recruiting

  • Research Site

    Lérida, 25198
    Spain

    Site Not Available

  • Research Site

    Madrid, 28040
    Spain

    Active - Recruiting

  • Research Site

    Málaga, 29010
    Spain

    Active - Recruiting

  • Research Site

    Pamplona, 31008
    Spain

    Active - Recruiting

  • Research Site

    Santiago de Compostela, 15706
    Spain

    Site Not Available

  • Research Site

    Lund, 221 85
    Sweden

    Active - Recruiting

  • Research Site

    Solna, 17176
    Sweden

    Active - Recruiting

  • Research Site

    Växjö, 35185
    Sweden

    Active - Recruiting

  • Research Site

    Kaohsiung, 83301
    Taiwan

    Active - Recruiting

  • Research Site

    Taichung,
    Taiwan

    Active - Recruiting

  • Research Site

    Tainan, 704
    Taiwan

    Active - Recruiting

  • Research Site

    Taipei, 10002
    Taiwan

    Active - Recruiting

  • Research Site

    Taoyuan, 333
    Taiwan

    Active - Recruiting

  • Research Site

    Bangkok, 10700
    Thailand

    Active - Recruiting

  • Research Site

    Chiang Mai, 50200
    Thailand

    Active - Recruiting

  • Research Site

    Dusit, 10300
    Thailand

    Active - Recruiting

  • Research Site

    Hat Yai, 90110
    Thailand

    Active - Recruiting

  • Research Site

    Khon Kaen, 40002
    Thailand

    Active - Recruiting

  • Research Site

    Lampang, 52000
    Thailand

    Active - Recruiting

  • Research Site

    Ratchathewi, 10400
    Thailand

    Active - Recruiting

  • Research Site

    Ankara, 6100
    Turkey

    Active - Recruiting

  • Research Site

    Antalya, 07070
    Turkey

    Active - Recruiting

  • Research Site

    Goztepe Istanbul,
    Turkey

    Active - Recruiting

  • Research Site

    Karsiyaka, 35575
    Turkey

    Active - Recruiting

  • Research Site

    Kayseri, 38039
    Turkey

    Site Not Available

  • Research Site

    Malatya, 44280
    Turkey

    Active - Recruiting

  • Research Site

    Samsun, 55200
    Turkey

    Active - Recruiting

  • Research Site

    Derry, BT47 6SB
    United Kingdom

    Active - Recruiting

  • Research Site

    Guildford, CU2 7XX
    United Kingdom

    Active - Recruiting

  • Research Site

    London, SE1 9RT
    United Kingdom

    Active - Recruiting

  • Research Site

    Taunton, TA1 5DA
    United Kingdom

    Active - Recruiting

  • Research Site

    York, YO21 8HE
    United Kingdom

    Active - Recruiting

  • Research Site

    Tucson, Arizona 85719
    United States

    Active - Recruiting

  • Research Site

    Fountain Valley, California 92708
    United States

    Active - Recruiting

  • Research Site

    Glendale, California 91204
    United States

    Active - Recruiting

  • Research Site

    Los Angeles, California 90048
    United States

    Site Not Available

  • Research Site

    Napa, California 94558
    United States

    Site Not Available

  • Research Site

    Newport Beach, California 92663
    United States

    Active - Recruiting

  • Research Site

    San Francisco, California 94158
    United States

    Active - Recruiting

  • Research Site

    Santa Barbara, California 93105
    United States

    Site Not Available

  • Research Site

    Santa Rosa, California 92805
    United States

    Active - Recruiting

  • Research Site

    Aurora, Colorado 80045
    United States

    Active - Recruiting

  • Research Site

    New Haven, Connecticut 06510
    United States

    Active - Recruiting

  • Research Site

    Newark, Delaware 19713
    United States

    Active - Recruiting

  • Research Site

    Quincy, Illinois 62305
    United States

    Active - Recruiting

  • Research Site

    Fort Wayne, Indiana 46804
    United States

    Active - Recruiting

  • Research Site

    Louisville, Kentucky 40202
    United States

    Site Not Available

  • Research Site

    Baton Rouge, Louisiana 70809
    United States

    Suspended

  • Research Site

    Covington, Louisiana 70433
    United States

    Active - Recruiting

  • Research Site

    Annapolis, Maryland 21401
    United States

    Active - Recruiting

  • Research Site

    Baltimore, Maryland 21202
    United States

    Active - Recruiting

  • Research Site

    Boston, Massachusetts 02215
    United States

    Active - Recruiting

  • Research Site

    Detroit, Michigan 48236
    United States

    Active - Recruiting

  • Research Site

    Grand Rapids, Michigan 49503
    United States

    Active - Recruiting

  • Research Site

    Hannibal, Missouri 63401
    United States

    Active - Recruiting

  • Research Site

    Saint Louis, Missouri 63110
    United States

    Active - Recruiting

  • Research Site

    Omaha, Nebraska 68130
    United States

    Active - Recruiting

  • Research Site

    Camden, New Jersey 08103
    United States

    Active - Recruiting

  • Research Site

    Brooklyn, New York 11220
    United States

    Site Not Available

  • Research Site

    Mineola, New York 11501
    United States

    Site Not Available

  • Research Site

    New York, New York 10016
    United States

    Site Not Available

  • Research Site

    Durham, North Carolina 27710
    United States

    Site Not Available

  • Research Site

    Gresham, Oregon 97030
    United States

    Active - Recruiting

  • Research Site

    Philadelphia, Pennsylvania 19104
    United States

    Active - Recruiting

  • Research Site

    Pittsburgh, Pennsylvania 15213
    United States

    Site Not Available

  • Research Site

    York, Pennsylvania 17403
    United States

    Site Not Available

  • Research Site

    Providence, Rhode Island 02903
    United States

    Site Not Available

  • Research Site

    Greenville, South Carolina 29607
    United States

    Active - Recruiting

  • Research Site

    Chattanooga, Tennessee 37404
    United States

    Active - Recruiting

  • Research Site

    Nashville, Tennessee 37203
    United States

    Active - Recruiting

  • Research Site

    Dallas, Texas 75246
    United States

    Active - Recruiting

  • Research Site

    Fort Worth, Texas 76104
    United States

    Site Not Available

  • Research Site

    Houston, Texas 77030
    United States

    Active - Recruiting

  • Research Site

    San Antonio, Texas 78229
    United States

    Active - Recruiting

  • Research Site

    Falls Church, Virginia 22042
    United States

    Active - Recruiting

  • Research Site

    Leesburg, Virginia 20176
    United States

    Active - Recruiting

  • Research Site

    Midlothian, Virginia 23114
    United States

    Active - Recruiting

  • Research Site

    Norfolk, Virginia 23502
    United States

    Active - Recruiting

  • Research Site

    Tacoma, Washington 98405
    United States

    Active - Recruiting

  • Research Site

    Hanoi, 100000
    Vietnam

    Active - Recruiting

  • Research Site

    Ho Chi Minh, 70000
    Vietnam

    Active - Recruiting

  • Research Site

    Ho Chi Minh city, 700000
    Vietnam

    Active - Recruiting

  • Research Site

    Vinh, 460000
    Vietnam

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.